2001
DOI: 10.2174/1381612013397889
|View full text |Cite
|
Sign up to set email alerts
|

Small Molecule Crystallography in Drug Design

Abstract: Crystal structures of small molecules (i.e. isolated ligands) are a source of valuable structural information helpful in the process of drug design (pharmacophore model elaborations, 3D QSAR, docking, and de novo design). Indeed, structural data obtained from small molecules crystallography can approach ligand-receptor binding by providing unique structural features both about the conformation (internal geometry) of the ligand (s) and about the intermolecular interaction potentially occurring within the active… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2003
2003
2021
2021

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 13 publications
(5 citation statements)
references
References 69 publications
0
5
0
Order By: Relevance
“…Using the structures of drugs to map receptor binding sites is a useful approach (see for example [189] in this journal). Three-dimensional structures are available for several hypoglycemic compounds including glibenclamide [190], glimerperide, and repaglinide [149].…”
Section: An Unexpected Source Of Structural Insightmentioning
confidence: 99%
“…Using the structures of drugs to map receptor binding sites is a useful approach (see for example [189] in this journal). Three-dimensional structures are available for several hypoglycemic compounds including glibenclamide [190], glimerperide, and repaglinide [149].…”
Section: An Unexpected Source Of Structural Insightmentioning
confidence: 99%
“…X-ray crystallography is the primary method for determining the absolute configuration of a molecule and results from crystallographic studies provide unambiguous, accurate, and reliable 3-dimensional structural parameters, which are prerequisites for rational drug design and structure-based functional studies. Thus the role of crystallography in drug design is widely recognized (Cachau and Podjarny, 2005; Deschamps, 2005; Williams et al, 2005; Blundell et al, 2002; Wouters and Ooms, 2001). …”
Section: Introductionmentioning
confidence: 99%
“…One of the critical steps in rational drug design is obtaining knowledge of the structure of the new drug candidates, and single-crystal X-ray diffraction (SCXD) is one of the most powerful methods for gaining this fundamental information, which can be used to guide the drug-design studies in connection with other technologies such as pharmacophore model elaborations, 3D QSAR, docking, and de novo design. SCXD has thus become an essential tool for drug development to unambiguously determine the threedimensional structures of molecules, which eventually paves the way for rapid development of new molecules (Wouters & Ooms, 2001). Moreover, during the drug-development process, another important issue lies in understanding the crystal packing of the active pharmaceutical ingredient (drug substance) for suitable formulation development.…”
Section: Chemical Contextmentioning
confidence: 99%